UroGen Pharma Ltd. Payments to Acquire Marketable Securities
UroGen Pharma Ltd. (URGN) reported Payments to Acquire Marketable Securities of $24.78 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-05
- UroGen Pharma Ltd. payments to acquire marketable securities for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- UroGen Pharma Ltd. payments to acquire marketable securities for the quarter ending 2026-03-31 was $24.78M, a 62.65% decline year-over-year.
- UroGen Pharma Ltd. payments to acquire marketable securities for the quarter ending 2025-12-31 was $539.00K, a 94.16% decline year-over-year.
- UroGen Pharma Ltd. payments to acquire marketable securities for the quarter ending 2025-09-30 was $8.72M, a 92.66% decline year-over-year.
- UroGen Pharma Ltd. payments to acquire marketable securities for fiscal 2025 was $77.40M, a 39.54% decline from fiscal 2024.
- UroGen Pharma Ltd. payments to acquire marketable securities for fiscal 2024 was $128.02M, a 156.91% increase from fiscal 2023.
- UroGen Pharma Ltd. payments to acquire marketable securities for fiscal 2023 was $49.83M, a 20.91% decline from fiscal 2022.
- UroGen Pharma Ltd. payments to acquire marketable securities for fiscal 2022 was $63.01M, a 21.41% increase from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $24.78M 10-Q · filed 2026-08-05 | $25.32M derived: sum of 3 quarters · filed 2026-08-05 | $34.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $24.78M 10-Q · filed 2026-05-06 | $25.32M derived: sum of 2 quarters · filed 2026-05-06 | $34.04M derived: sum of 3 quarters · filed 2026-05-06 | $35.83M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $539.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $9.26M derived: sum of 2 quarters · filed 2026-03-02 | $11.05M derived: sum of 3 quarters · filed 2026-08-05 | $77.40M 10-K · filed 2026-03-02 |
| 2025-09-30 | $8.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $10.51M derived: sum of 2 quarters · filed 2026-08-05 | $76.86M 10-Q · filed 2025-11-06 | $86.09M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $68.14M 10-Q · filed 2026-08-05 | $77.37M derived: sum of 3 quarters · filed 2026-08-05 | $196.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $66.35M 10-Q · filed 2026-05-06 | $75.58M derived: sum of 2 quarters · filed 2026-05-06 | $194.37M derived: sum of 3 quarters · filed 2026-05-06 | $194.37M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $9.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $128.02M derived: sum of 2 quarters · filed 2026-03-02 | $128.02M derived: sum of 3 quarters · filed 2026-03-02 | $128.02M 10-K · filed 2026-03-02 |
| 2024-09-30 | $118.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $118.79M derived: sum of 2 quarters · filed 2025-11-06 | $118.79M 10-Q · filed 2025-11-06 | $133.62M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $14.82M derived: sum of 3 quarters · filed 2025-08-07 | $25.66M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | $14.82M derived: sum of 2 quarters · filed 2025-05-12 | $25.66M derived: sum of 3 quarters · filed 2025-05-12 | $25.66M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $14.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $25.66M derived: sum of 2 quarters · filed 2025-03-10 | $25.66M derived: sum of 3 quarters · filed 2025-03-10 | $49.83M 10-K · filed 2025-03-10 |
| 2023-09-30 | $10.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $10.83M derived: sum of 2 quarters · filed 2024-11-06 | $35.01M 10-Q · filed 2024-11-06 | $35.01M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $24.18M 10-Q · filed 2024-08-13 | $24.18M derived: sum of 3 quarters · filed 2024-08-13 | $87.19M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $24.18M 10-Q · filed 2024-05-13 | $24.18M derived: sum of 2 quarters · filed 2024-05-13 | $87.19M derived: sum of 3 quarters · filed 2024-05-13 | $87.19M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $63.01M derived: sum of 2 quarters · filed 2024-03-14 | $63.01M derived: sum of 3 quarters · filed 2024-03-14 | $63.01M 10-K · filed 2024-03-14 |
| 2022-09-30 | $63.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $63.01M derived: sum of 2 quarters · filed 2023-11-14 | $63.01M 10-Q · filed 2023-11-14 | $63.31M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $304.00K derived: sum of 3 quarters · filed 2023-08-10 | $10.24M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $304.00K derived: sum of 2 quarters · filed 2023-05-11 | $10.24M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $304.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $10.24M derived: sum of 2 quarters · filed 2023-03-24 | $51.90M 10-K · filed 2023-03-24 | |
| 2021-09-30 | $9.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $51.59M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $41.66M 10-Q · filed 2022-08-11 | |||
| 2020-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $0.00 derived: sum of 2 quarters · filed 2022-03-21 | $20.31M derived: sum of 3 quarters · filed 2022-03-21 | $29.69M 10-K · filed 2022-03-21 |
| 2020-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $20.31M derived: sum of 2 quarters · filed 2021-11-15 | $29.69M 10-Q · filed 2021-11-15 | $58.52M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $20.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $29.69M 10-Q · filed 2021-08-04 | $58.52M derived: sum of 3 quarters · filed 2021-08-04 | $85.23M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $9.38M 10-Q · filed 2021-05-13 | $38.21M derived: sum of 2 quarters · filed 2021-05-13 | $64.92M derived: sum of 3 quarters · filed 2021-05-13 | |
| 2019-12-31 | $28.83M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $55.54M derived: sum of 2 quarters · filed 2021-03-18 | $197.69M 10-K · filed 2021-03-18 | |
| 2019-09-30 | $26.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $168.85M 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $142.14M 10-Q · filed 2020-08-10 | |||
| 2017-12-31 | $36.00M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |